These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31693224)

  • 41. Addition of plerixafor for CD34+ cell mobilization in six healthy stem cell donors ensured satisfactory grafts for transplantation.
    Hauge AW; Haastrup EK; Sengeløv H; Minulescu L; Dickmeiss E; Fischer-Nielsen A
    Transfusion; 2014 Apr; 54(4):1055-8. PubMed ID: 23944772
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in Japanese healthy donors: a prospective study.
    Sato K; Ishiyama K; Aoki G; Maruyama H; Tsuji N; Tanabe M; Zaimoku Y; Sato H; Yamazaki H; Yamaguchi M; Takami A; Nakao S
    Int J Hematol; 2019 Dec; 110(6):648-653. PubMed ID: 31542851
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
    Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A
    Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical impact of a new automated system employed for peripheral blood stem cell collection.
    Del Fante C; Perotti C; Viarengo G; Bellotti L; Parisi C; Marchesi A; Tinelli C; Salvaneschi L
    J Clin Apher; 2006 Dec; 21(4):227-32. PubMed ID: 16847939
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Feasibility and cost analysis of day 4 granulocyte colony-stimulating factor mobilized peripheral blood progenitor cell collection from HLA-matched sibling donors.
    Newell LF; Shoop KM; Knight RJ; Murray SN; Kwock RP; Jacoby CE; Slater S; Allen BE; Ottowa C; Cota B; Appel PL; Cook RJ; Maziarz RT; Meyers G
    Cytotherapy; 2019 Jul; 21(7):725-737. PubMed ID: 31085121
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
    Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
    Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization.
    Passos-Coelho JL; Braine HG; Davis JM; Huelskamp AM; Schepers KG; Ohly K; Clarke B; Wright SK; Noga SJ; Davidson NE
    J Clin Oncol; 1995 Mar; 13(3):705-14. PubMed ID: 7533827
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differences in Cellular Composition of Peripheral Blood Stem Cell Grafts from Healthy Stem Cell Donors Mobilized with Either Granulocyte Colony-Stimulating Factor (G-CSF) Alone or G-CSF and Plerixafor.
    Teipel R; Oelschlägel U; Wetzko K; Schmiedgen M; Kramer M; Rücker-Braun E; Hölig K; von Bonin M; Heidrich K; Fuchs A; Ordemann R; Kroschinsky F; Bornhäuser M; Hütter G; Schmidt H; Ehninger G; Schetelig J; Heidenreich F
    Biol Blood Marrow Transplant; 2018 Nov; 24(11):2171-2177. PubMed ID: 29935214
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A matched-pair analysis reveals marginally reduced CD34+ cell mobilization on second occasion in 27 related donors who underwent peripheral blood stem cell collection twice at the same institution.
    Velier M; Granata A; Bramanti S; Calmels B; Furst S; Legrand F; Harbi S; Faucher C; Devillier R; Blaise D; Mfarrej B; Lemarie C; Chabannon C
    Transfusion; 2019 Nov; 59(11):3442-3447. PubMed ID: 31625183
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease.
    Weaver CH; Schwartzberg L; Li W; Hazelton B; West W
    Bone Marrow Transplant; 1996 May; 17(5):715-21. PubMed ID: 8733687
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mobilization kinetics of CD34+/Thy-1dim progenitor cells during recombinant human granulocyte-colony-stimulating factor administration in normal donors.
    Seong C; Durett A; Mirza N; Huh Y; Anderlini P; Champlin R
    Transfusion; 1997 Apr; 37(4):406-10. PubMed ID: 9111278
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Factors associated with successful mobilization of progenitor hematopoietic stem cells among patients with lymphoid malignancies.
    Ameen RM; Alshemmari SH; Alqallaf D
    Clin Lymphoma Myeloma; 2008 Apr; 8(2):106-10. PubMed ID: 18501104
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin.
    Brugger W; Birken R; Bertz H; Hecht T; Pressler K; Frisch J; Schulz G; Mertelsmann R; Kanz L
    Br J Haematol; 1993 Jul; 84(3):402-7. PubMed ID: 7692928
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Granulocyte colony-stimulating factor-mobilized peripheral blood stem cells in beta-thalassemia patients: kinetics of mobilization and composition of apheresis product.
    Li K; Wong A; Li CK; Shing MM; Chik KW; Tsang KS; Lai H; Leung TF; Yuen PM
    Exp Hematol; 1999 Mar; 27(3):526-32. PubMed ID: 10089916
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vigorous exercise mobilizes CD34+ hematopoietic stem cells to peripheral blood via the β
    Agha NH; Baker FL; Kunz HE; Graff R; Azadan R; Dolan C; Laughlin MS; Hosing C; Markofski MM; Bond RA; Bollard CM; Simpson RJ
    Brain Behav Immun; 2018 Feb; 68():66-75. PubMed ID: 29017969
    [TBL] [Abstract][Full Text] [Related]  

  • 56. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft.
    Dreger P; Haferlach T; Eckstein V; Jacobs S; Suttorp M; Löffler H; Müller-Ruchholtz W; Schmitz N
    Br J Haematol; 1994 Jul; 87(3):609-13. PubMed ID: 7527648
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs.
    Ria R; Gasparre T; Mangialardi G; Bruno A; Iodice G; Vacca A; Dammacco F
    Bone Marrow Transplant; 2010 Feb; 45(2):277-81. PubMed ID: 19584820
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Single-dose pegfilgrastim for the mobilization of allogeneic CD34+ peripheral blood progenitor cells in healthy family and unrelated donors.
    Kroschinsky F; Hölig K; Poppe-Thiede K; Zimmer K; Ordemann R; Blechschmidt M; Oelschlaegel U; Bornhauser M; Rall G; Rutt C; Ehninger G
    Haematologica; 2005 Dec; 90(12):1665-71. PubMed ID: 16330441
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, interleukin-1 beta (IL-1 beta), IL-6, IL-3, interferon-gamma, and erythropoietin.
    Brugger W; Möcklin W; Heimfeld S; Berenson RJ; Mertelsmann R; Kanz L
    Blood; 1993 May; 81(10):2579-84. PubMed ID: 7683923
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Analysis of stem cell apheresis products using intermediate-dose filgrastim plus large volume apheresis for allogeneic transplantation.
    Engelhardt M; Bertz H; Wäsch R; Finke J
    Ann Hematol; 2001 Apr; 80(4):201-8. PubMed ID: 11401085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.